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INTRODUCTION
Prader-Willi syndrome (PWS) is a contiguous gene syn-
drome resulting from the deletion of the paternal copies of
the imprinted SNRPN gene and possibly other genes. The
condition is characterized by diminished fetal activity, obe-
sity, muscular hypotonia, mental retardation, short stature,
hypogonadotropic hypogonadism, and uncontrollable hyper-
phagia (1-3). 
Because neonates with PWS are profoundly hypotonic,
hyporeflexia and poor feeding are often encountered due to
diminished swallowing and sucking reflexes, which in many
cases necessitates gavage feeding during the infantile period.
These feeding difficulties generally improve by the age of 6
months. However, from 12 to 18 months onward, uncon-
trollable hyperphagia causes major somatic and psychologi-
cal problems (4).
In contrast to infants, adolescents with PWS typically show
insatiable hunger (5), and any attempt to reduce food intake
in these adolescents often leads to serious psychological and
behavioral problems with the home environment becoming
intolerable in some children. Patients rarely survive beyond
25 to 30 yr of age due to diabetes and cardiac failure. How-
ever, strict weight control can greatly reduce the risk of both
diabetes and cardiac failure and slightly affect survival (6).
Therefore, proper weight control would substantially improve
the quality of life and survival of both adolescents and adults
with PWS. 
Typically subjects with PWS eat for a longer time than
obese or normal weight subjects. In PWS, it has been reported
that 56% of the eating curves are non-decelerating, compared
with 10% in the normal weight group and 30% in the obese
group (7).
Ghrelin is a novel peptide that acts on the growth hormone
(GH) secretagogue receptor in the pituitary and hypothala-
mus. Ghrelin also appears to play a role in energy homeosta-
sis, which is a determinant of plasma ghrelin concentration
because ghrelin acutely stimulates the appetite and GH secre-
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Marked Suppression of Ghrelin Concentration by Insulin in Prader-Willi
Syndrome
The plasma ghrelin has been reported to be elevated in Prader-Willi syndrome (PWS)
and modulated by insulin. It was hypothesized that insulin might have a more pro-
nounced effect on reducing plasma ghrelin in PWS patients, which would influence
appetite. This study investigated the degree of ghrelin suppression using an eug-
lycemic hyperinsulinemic clamp in children with PWS (n=6) and normal children
(n=6). After a 90-min infusion of insulin, the plasma ghrelin level decreased from a
basal value of 0.86± ±0.15 to 0.58± ±0.12 ng/mL in the controls, and from 2.38± ±0.76
to 1.12± ±0.29 ng/mL in children with PWS (p=0.011). The area under the curve
below the baseline level over the 90 min insulin infusion was larger in children with
PWS than in controls (-92.82± ±44.4 vs. -10.41± ±2.87 ng/mL/90 min) (p=0.011).
The insulin sensitivity measured as the glucose infusion rate at steady state was
similar in the two groups (p=0.088). The decrease in the ghrelin levels in response
to insulin was more pronounced in the children with PWS than in the controls. How-
ever, the level of ghrelin was always higher in the children with PWS during the clamp
study. This suggests that even though insulin sensitivity to ghrelin is well maintained,
an increase in the baseline ghrelin levels is characteristic of PWS. 
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tion in rodents and humans, and the chronic administration
to rodents causes obesity (8-11). The fasting plasma ghrelin
levels are lower in obese subjects than in lean controls (12-
14), and are elevated in patients with anorexia nervosa (14).
Fasting increases the plasma ghrelin level, which then decreas-
es after feeding (15-17). However, grossly elevated plasma
ghrelin levels have been demonstrated in PWS adults (4) and
children (6, 18), and recently, a 3- to 4- fold increase in the
ghrelin levels was reported in PWS patients over a 24-hr period
(18, 19). 
Insulin is a physiologic and dynamic modulator of plasma
ghrelin (20). The inhibitory effect of insulin on ghrelin secre-
tion has been reported to be independent of glucose, even
though glucose may have an additional effect (21, 22). More-
over, meal-related ghrelin suppression does not appear to be
directly regulated by glucose or insulin (23).
Although the negative correlation between fasting ghre-
lin levels and obesity in non-PWS subjects may be the result
of insulin resistance and hyperinsulinemia suppressing the
secretion of ghrelin (21, 22), hyperghrelinemia in PWS can-
not be solely explained by the reduced visceral adiposity and
relative hypoinsulinemia (24). Therefore, insulin might pro-
foundly lower plasma ghrelin levels, and influence appetite
in patients with PWS.
The aim of this study was to clarify the relationship between
plasma ghrelin and insulin and to evaluate the potential thera-
peutic benefit of using insulin to lower plasma ghrelin in
children with PWS. Therefore, this study investigated the
relationship between plasma ghrelin and insulin in children
with PWS (n=6) and normal children (n=6), and compared
the degree of ghrelin suppression using an euglycemic hyper-
insulinemic clamp.
MATERIALS AND METHODS
Subjects and protocol
Six children with PWS (all male) aged 12.17±0.87 yr
with a mean body mass index (BMI) of 29.14±4.03 kg/m2,
and 6 age-, gender-, and BMI matched controls (males, 12.33
±0.92 yr with a BMI of 30.50±3.94 kg/m2) were enrolled
in this study (Table 1). The subjects were admitted to the
Samsung Medical Center at Sungkyunkwan University the
day before the clamp procedure. After a 10-hr overnight fast,
an intravenous catheter was placed in the antecubital vein
to infuse insulin and glucose. Another catheter was placed
retrograde in the dorsal vein of the contralateral hand for
blood withdrawal. The arm fitted with the insulin/glucose
infusing catheter was placed in a heating pad to arterialize
the blood. Regular human insulin (40 mIU/m2/min) was
infused for two hours and a variable infusion of 20% dextrose
was administered to maintain plasma glucose at the fasting
level. Subsequently, the insulin infusion was discontinued
and the 20% glucose infusion was gradually tapered to main-
tain the plasma glucose at the same level for another hour.
During the procedure, arterial plasma glucose was measured
every 5 min to guide the glucose infusion. Blood samples
were collected at -15 min (before insulin infusion), and every
15 min during the next 180 min to monitor plasma insulin
and ghrelin concentrations. The degree of ghrelin suppres-
sion was measured by the difference between 0 min and the
measurement time. Insulin sensitivity was defined as glucose
infusion rate required to maintain a basal plasma glucose con-
centration during the final 30 min (90-120 min) of the eug-
lycemic clamp.
The Institutional Review Board approved the experimen-
tal protocol and informed consent was obtained from the par-
ents of the patients and controls in all cases.
Biochemical analysis
The plasma glucose was measured using a YSI model 2300
dual analyzer (Yellow Springs Instrument Co., Yellow Springs,
OH). The plasma insulin was measured using a commercially
available immuno-radiometric assay kit (BioSource Europe
S.A.) with a detection limit of 1 uIU/mL and intra-, and inter-
assay coefficients of variation of <10%. The plasma ghrelin
levels were measured in duplicate using a commercial ELISA
kit (Phoenix Pharmaceuticals, Belmont, CA). The inter- and
intra-assay coefficients of variance were less than 10%. The
lower and upper limits of detection for this assay were 0.75
ng/mL and 100 ng/mL.
All samples from a single participant were measured in the
same assay.
Statistical analysis
The areas under the curve (AUC) below baseline were cal-
culated using the trapezoid method. The AUCs are expressed
Subject Age (yr) BMI (kg/m
2)
BMI 
percentile
C1 16 45.0 >95
C2 14 35.2 >95
C3 11 21.0 75-85
C4 11 35.78 >95
C5 12 24.05 90-95
C6 10 21.95 >95
Mean±SEM 12.33±0.92 30.50±3.94
P1 13 28.0 >95
P2 11 33.04 >95
P3 16 47.11 >95
P4 11 20.53 75-85
P5 10 22.7 >95
P6 12 23.43 90-95
Mean±SEM 12.17±0.87 29.14±4.03
Table 1. Characteristics of the male study subjects (C1-6: Con-
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as units per 90 or 120 min below each subject’s fasting base-
line level, and were compared using the Mann-Whitney test.
The differences in the plasma ghrelin levels between 0 and
90 min in each subject were calculated, and the values from
the two groups were compared using the Mann-Whitney test.
The glucose infusion rates at steady state (90-120 min) were
also compared between groups using the Mann-Whitney test.
All statistical analyses were performed using SPSS software
(SPSS Inc., Chicago, IL, U.S.A.). The data is expressed as the
mean±SEM. p values <0.05 were considered significant.
RESULTS
The mean insulin level during insulin infusion (15 min to
120 min) in the control and PWS group was 92.09±6.36
mIU/mL and 81.48±3.21 mIU/mL, respectively, which was
not significantly different (Fig. 1). The plasma ghrelin level
in the control and PWS groups over the 90 min period of
insulin infusion was reduced from a basal value of 0.86±0.15
to 0.58±0.12 ng/mL and 2.38±0.76 to 1.12±0.29 ng/
mL, respectively. The plasma ghrelin levels were relatively
constant at these reduced levels until 15 min after the insulin
infusion had been discontinued (Fig. 2, 3). 
The plasma ghrelin level was suppressed maximally at 90
min after insulin infusion by 26.81±4.66% in the controls
and by 47.95±5.15% in the PWS group (Fig. 2, 3). The
degree of ghrelin suppression was higher in the PWS group
after the 90 min infusion of insulin infusion than in the con-
trol (p=0.011) (Fig. 3). However, the ghrelin levels in the
PWS patients were not suppressed to a level lower that of
the control during the study period (Fig. 2).
The AUC below baseline was higher for the PWS group
than in the control during the 90 min of insulin infusion
(-92.82±44.4 vs. -10.41±2.87 ng/mL/90 min) (p=0.011)
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Fig. 1. The mean insulin level during the insulin infusion (15 min
to 120 min) in the control and PWS group was 92.09±6.36 mIU/
mL and 81.48±3.21 mIU/mL, respectively, which was not statis-
tically different.
Fig. 2. The plasma ghrelin level in the control and PWS groups
over the 90 min period of insulin infusion was reduced from a basal
value of 0.86±0.15 to 0.58±0.12 ng/mL and 2.38±0.76 to 1.12
±0.29 ng/mL, respectively. The plasma ghrelin levels were rela-
tively constant at these reduced levels until 15 min after the insulin
infusion had been discontinued. The plasma ghrelin level was sup-
pressed maximally at 90 min after insulin infusion. The plasma ghre-
lin levels in PWS patients were not suppressed to a level lower that
of the control during the study period.
Fig. 3. The plasma ghrelin level was suppressed maximally at 90
min after insulin infusion by 26.81±4.66% in the controls and by
47.95±5.15% in the PWS group. The degree of ghrelin suppres-
sion was higher in the PWS group after the 90 min infusion of insulin
infusion than in the control (p=0.011).
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Fig. 4. The area under the curve (AUC) below the baseline was
higher for the PWS group than in the control during the 90 min of
insulin infusion (-92.82±44.4 vs. -10.41±2.87 ng/mL/ 90 min)
(p=0.011) and during the entire insulin infusion period of 120 min
(-130.17±59.51 vs. -16.54±4.04 ng/mL/120 min) (p=0.011).
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and during the entire insulin infusion period of 120 min
(-130.17±59.51 vs. -16.54±4.04 ng/mL/120 min) (p=
0.011) (Fig. 4).
The mean glucose infusion rate at steady state (90-120 min)
in the PWS patients (5.93±0.93 mg/kg/min) was higher
than in the controls (2.59±1.17 mg/kg/min), but this was
not significant (p=0.088) (Fig. 5).
DISCUSSION
The insulin-induced suppression of ghrelin was more pro-
found in the children with PWS after the 90-min infusion
of insulin than in the controls even though the mean insulin
level was similar in both groups. Therefore, at a given insulin
level, the plasma level of ghrelin was reduced more effectively
in the children with PWS than in the normal controls. How-
ever, it should be noted that the lowest ghrelin level in the
PWS group was always higher than in the control group at
the corresponding times during the study period. The results
of this clamp study are reminiscent of those of a previous
24-hr monitoring study as far as the relationship between
ghrelin and insulin are concerned.
In a previous study when insulin and ghrelin were moni-
tored for 24 hr, the peak plasma ghrelin level in the children
with PWS was 3-4 times higher than in the normal control,
while the peak plasma insulin levels in the children with PWS
was similar to that in the controls. After meals, the peaked
ghrelin level returned to the baseline in both PWS and con-
trol groups. However, the baseline level of ghrelin was always
higher in the children with PWS (17). 
Recently, it was demonstrated that in the gastric body and
fundus, there were 2 to 3 fold increases in the number of ghre-
lin expressing cells (GECs) (p<0.001) and in the amount of
ghrelin (p<0.018) in PWS patients compared with the con-
trol groups. Therefore, the baseline increase in ghrelin might
be related to the hyperplasia of GECs, which means that the
absolute increase in the number of GECs might be related to
the baseline increase in the ghrelin level in this study (25). 
Overall, the increase in the basal ghrelin levels is a promi-
nent finding in this study and the decrease in ghrelin in res-
ponse to insulin was more pronounced in the children with
PWS than in the controls. 
Although the direct orexigenic effect of ghrelin in its phy-
siologic concentration range has not been elucidated in rodents
or humans, the link between insulin and ghrelin was demon-
strated in type I diabetes patients (26). It was shown that
insulin is essential for meal-induced plasma ghrelin suppres-
sion, and that basal insulin availability is sufficient to suppress
postprandial ghrelin in type 1 diabetic patients. It was con-
cluded that the lack of meal-induced ghrelin suppression
caused by a severe insulin deficiency might explain the hyper-
phagia in uncontrolled type 1 diabetic subjects. Interesting-
ly, the hyperphagia in uncontrolled type 1 diabetics is simi-
lar to the incessant eating of PWS patients. Excessive eating
in both diseases is associated with an elevated plasma ghre-
lin level, and a physiologic amount of insulin can effectively
suppress the surge in ghrelin within an hour. These results
also demonstrate that insulin plays a key role in regulating
the postprandial ghrelin concentrations. Therefore, insulin
might be a decisive signal that ensures postprandial plasma
ghrelin suppression in both diseases. However, insulin-induced
ghrelin suppression is more pronounced in PWS patients
than in uncontrolled diabetes patients, and the nadir of ghre-
lin suppression is also higher in PWS patients.
It is evident that ghrelin is released by the consumption of
carbohydrate-rich meals, and that a decrease in the plasma
ghrelin level is paralleled by an increase in plasma insulin
level (13, 16, 17, 27). Supportive evidence on the inhibitory
role of insulin on ghrelin secretion was provided by three
studies (20-22). On the other hand, two other studies denied
the role of insulin in ghrelin control (23, 28). The data in the
present study are in line with the data reported in references
20-22, i.e., ghrelin was suppressed by insulin was observed
while maintaining euglycemia using an euglycemic clamp
technique. Therefore, the suppression of ghrelin appears to
be due to insulin, not glucose. Moreover, an increase in the
ghrelin level in the absence of hyperglycemia can contribute
to the attenuation of postprandial release of insulin, which
is supported by several studies (29-31).
Negative relationships have been observed between fasting
ghrelin and the measures of insulin resistance (24). Gold-
stone et al. reported that a selected reduction in visceral adi-
posity in PWS patients has protective effect against the ad-
verse metabolic consequences of obesity, such as insulin resis-
tance (24). In the present study, an increasing tendency was
found with respect to the glucose infusion rate at steady state
in PWS patients but this was not significant. However, the
lack of significance might have been due to the small num-
ber of cases examined.
In conclusion, the insulin-induced suppression of ghrelin
was found to be more pronounced in the children with PWS
than in the normal controls. Moreover, the baseline levels of
Fig. 5. The mean glucose infusion rate at the steady state (90-120
min) in the PWS patients (5.93±0.93 mg/kg/min) was higher than
in the controls (2.59±1.17 mg/kg/min), but this was not significant
(p=0.088).
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5.93ghrelin in the children with PWS were always higher than
those of the controls. This suggests that even though insulin
sensitivity to ghrelin is well maintained in PWS patients,
the increase in the baseline levels of the ghrelin is a charac-
teristic finding of PWS. It appears that the regulatory mech-
anisms of ghrelin are different in PWS patients, which might
be of physiological importance in the obesity associated with
PWS. However, more study will be needed to determine the
precise regulatory mechanism of ghrelin in normal children
and children with PWS. 
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